Why the study?
Does sulfinpyrazone alter hemostatic parameters in patients with recent myocardial infarction?
Does sulfinpyrazone alter hemostatic parameters in patients with recent myocardial infarction?
Answers are grounded in this paper and cite their sources.
Sulfinpyrazone modifies specific ex vivo platelet function parameters in post-myocardial infarction patients, though the prognostic significance of these surrogate changes requires correlation with clinical endpoints.
SUMMARY In the Anturan Reinfarction Italian Study (ARIS) some specific and quantitative hemostatic parameters are being investigated at different times and in different series of patients balanced for sulfinpyrazone (S) and placebo (P) in order to ascertain if one or more of these parameters may be considered as forecasting elements. A series of 186 myocardial infarction (m. i.) patients was randomly allocated to S and P 15–25 days after the m.i. episode, and tests performed at treatment allocation and after 1, 6 and 12 months. In comparison with 44 healthy volunteers, the results have provided striking confirmation of “hyperactive” platelets in the early phase of m.i.: the bleeding time (BT) was shorter, β‐thromboglobulin (β‐TG) increased, PF 4 release increased, heparin thrombin clotting time (HTCT) shorter, and platelet sensitivity to threshold concentrations of ADP and collagen increased. Significant changes in BT, P F 4 release and HTCT persisted at successive testing times. Platelet aggregation by low collagen concentrations was inhibited in the S subsample patients. In a different series of young male patients who had had a m.i. 6 months previously, it has been shown that the P treatment subsample presented shortened platelet production time (PPT), increased levels of plasma ‐TG and PF 4 and increased factor VIII:RAg compared with a matched control group. The S treatment subsample presented normalized PPT accompanied by reduction of VIlhRAg but not of β‐TG or PF 4 . plasma levels. It will be possible to evaluate the prognostic significance of these results only when the above pattern in the parameters can be correlated with the major and minor clinical events observed in patient follow‐up, that is, after ARIS closes. Prospective clinical trials with platelet anti‐aggregating agents were started when it was realized that for such drugs to be defined as anti‐thrombotic it was not sufficient to show that they had an effect on platelet function in vitro or ex vivo , and only the demonstration that they are efficacious in preventing specific clinical endpoints would justify defining them as antithrombotic.
No takes yet. Share an insight, caveat, or question.
M. Cortellaro (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: